Fortuna is a biotechnology company that provides forecasting and screening technology solutions for non-invasive embryo trait assessment.
Fortuna has raised $500K in total funding. The most recent round was Pre-Seed. The last funding was announced in March 2022.
Fortuna's investors include Y Combinator.
Fortuna is headquartered in Cambridge, United States.
Fortuna is a biotechnology company that provides forecasting and screening technology solutions for non-invasive embryo trait assessment.
Fortuna is at the Pre-Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Fortuna — Funding & Investors." VCBacked, March 29, 2022, https://www.vcbacked.co/company/fortuna-cambridge. Accessed October 22, 2026.
VCBacked. (2022). Fortuna — Funding & Investors. Retrieved October 22, 2026, from https://www.vcbacked.co/company/fortuna-cambridge
{{cite web |title=Fortuna — Funding & Investors |url=https://www.vcbacked.co/company/fortuna-cambridge |website=VCBacked |access-date=October 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated